Additive interaction between ultrasound-diagnosed metabolic dysfunction-associated steatotic liver disease and hyperuricemia on impaired fasting glucose: a large-scale cross-sectional study
- 1Health Management Center of the First Affiliated Hospital of Henan Polytechnic University (Jiaozuo Second People’s Hospital)
Abstract
Hyperuricemia and metabolic dysfunction-associated steatotic liver disease (MASLD) independently contribute to dysglycemia, yet their additive interaction on impaired fasting glucose (IFG) remains unquantified. In this cross-sectional study, 17,980 adults undergoing health examinations in Jiaozuo, China (2025) were analyzed. Hyperuricemia was defined by sex-specific thresholds and MASLD by ultrasonography. Participants were cross-classified into four exposure groups. Additive interaction was assessed through relative excess risk due to interaction (RERI), attributable proportion (AP), and synergy index (S) from fully adjusted logistic regression. Restricted cubic splines explored non-linear relationships, and sex-stratified analyses were performed. After full adjustment, the odds of IFG were 2.04 (95% CI 1.70–2.45) for isolated hyperuricemia, 2.85 (95% CI 2.50–3.25) for isolated MASLD, and 4.82 (95% CI 4.10–5.67) for their combination. A positive additive interaction was observed: RERI = 0.93 (95% CI 0.15–1.71; P = 0.019), AP = 0.19 (95% CI 0.05–0.34; P = 0.009), S = 1.34 (95% CI 1.02–1.76; P = 0.035). Spline curves showed a steeper increase in predicted probability beginning around 360 µmol/L in individuals with MASLD, whereas the rise was modest until approximately 420 µmol/L among those without. The interaction estimates appeared larger in women and non-obese participants. Hyperuricemia and MASLD display a positive additive interaction on IFG prevalence. The observed pattern supports considering the combination of elevated uric acid and hepatic steatosis as a marker for intensified glucose surveillance, particularly in women and lean individuals. Prospective studies are needed to evaluate its utility in screening and intervention.
Related
- Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study
- Hyperuricemia-related erectile dysfunction: mechanistic links and a translational framework for integrated traditional Chinese and western medicine
- Single-cell multi-omics reveals cellular atlases and cell–cell interaction networks in metabolic dysfunction-associated steatotic liver disease (MASLD)
- Joint association and interaction of lipoprotein(a) and hyperuricemia with long-term outcomes in chronic total occlusion
- Evaluation of Alterations in Serum Uric Acid Levels in Newly Diagnosed Overt Thyroid Dysfunction: A Prospective Observational Study From a Tertiary Care Center
BibTeX
@article{liang2026additive,
title = {{Additive interaction between ultrasound-diagnosed metabolic dysfunction-associated steatotic liver disease and hyperuricemia on impaired fasting glucose: a large-scale cross-sectional study}},
author = {Wenwen Liang and Pengchang Wang},
journal = {Scientific Reports},
year = {2026},
month = sep,
doi = {10.1038/s41598-026-71773-y},
url = {https://doi.org/10.1038/s41598-026-71773-y},
note = {CC BY},
}
RIS
TY - JOUR
TI - Additive interaction between ultrasound-diagnosed metabolic dysfunction-associated steatotic liver disease and hyperuricemia on impaired fasting glucose: a large-scale cross-sectional study
AU - Wenwen Liang
AU - Pengchang Wang
PY - 2026
DA - 2026/09/01
JO - Scientific Reports
DO - 10.1038/s41598-026-71773-y
UR - https://doi.org/10.1038/s41598-026-71773-y
AB - Hyperuricemia and metabolic dysfunction-associated steatotic liver disease (MASLD) independently contribute to dysglycemia, yet their additive interaction on impaired fasting glucose (IFG) remains unquantified. In this cross-sectional study, 17,980 adults undergoing health examinations in Jiaozuo, China (2025) were analyzed. Hyperuricemia was defined by sex-specific thresholds and MASLD by ultrasonography. Participants were cross-classified into four exposure groups. Additive interaction was assessed through relative excess risk due to interaction (RERI), attributable proportion (AP), and synergy index (S) from fully adjusted logistic regression. Restricted cubic splines explored non-linear relationships, and sex-stratified analyses were performed. After full adjustment, the odds of IFG were 2.04 (95% CI 1.70–2.45) for isolated hyperuricemia, 2.85 (95% CI 2.50–3.25) for isolated MASLD, and 4.82 (95% CI 4.10–5.67) for their combination. A positive additive interaction was observed: RERI = 0.93 (95% CI 0.15–1.71; P = 0.019), AP = 0.19 (95% CI 0.05–0.34; P = 0.009), S = 1.34 (95% CI 1.02–1.76; P = 0.035). Spline curves showed a steeper increase in predicted probability beginning around 360 µmol/L in individuals with MASLD, whereas the rise was modest until approximately 420 µmol/L among those without. The interaction estimates appeared larger in women and non-obese participants. Hyperuricemia and MASLD display a positive additive interaction on IFG prevalence. The observed pattern supports considering the combination of elevated uric acid and hepatic steatosis as a marker for intensified glucose surveillance, particularly in women and lean individuals. Prospective studies are needed to evaluate its utility in screening and intervention.
SN - 2045-2322
ER -